Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer
1. In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with residual human epidermal ...
Tag: HER2 breast cancer
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1. Invasive disease-free survival occurred in 19.7% of the T-DM1 group and 32.2% in the trastuzumab group, with an HR ...